Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06982534
EARLY_PHASE1

Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

View on ClinicalTrials.gov

Summary

This clinical trial is designed as a single-arm, open-label, single-center investigator-initiated early-phase study, with the primary objective of evaluating the safety of UTAA91 injection in subjects with refractory moderate-to-severe active systemic sclerosis.

Official title: Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2025-06

Completion Date

2040-01

Last Updated

2025-05-21

Healthy Volunteers

No

Interventions

BIOLOGICAL

UTAA91 injection

CAR-modified gamma delta T cells

Locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China